Marinomed Biotech AG (DE:93Z)
FRANKFURT:93Z
Want to see DE:93Z full AI Analyst Report?
Total Valuation
Marinomed Biotech AG has a market cap or net worth of €31.51M. The enterprise value is ―.
Market Cap€31.51M
Enterprise Value―
Share Statistics
Marinomed Biotech AG has 2,299,925 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,299,925
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Marinomed Biotech AG’s return on equity (ROE) is 0.67 and return on invested capital (ROIC) is -43.05%.
Return on Equity (ROE)0.67
Return on Assets (ROA)-0.47
Return on Invested Capital (ROIC)-43.05%
Return on Capital Employed (ROCE)-1.03
Revenue Per Employee296.24K
Profits Per Employee-219.19K
Employee Count31
Asset Turnover0.63
Inventory Turnover7.94
Valuation Ratios
The current PE Ratio of Marinomed Biotech AG is 2.3. Marinomed Biotech AG’s PEG ratio is ―.
PE Ratio2.3
PS Ratio0.00
PB Ratio0.00
Price to Fair Value-4.37
Price to FCF0.00
Price to Operating Cash Flow-5.57
PEG Ratio―
Income Statement
In the last 12 months, Marinomed Biotech AG had revenue of 9.18M and earned -6.79M in profits. Earnings per share was -4.48.
Revenue9.18M
Gross Profit1.14M
Operating Income-5.13M
Pretax Income-6.79M
Net Income-6.79M
EBITDA-3.62M
Earnings Per Share (EPS)-4.48
Cash Flow
In the last 12 months, operating cash flow was -4.14M and capital expenditures 0.00, giving a free cash flow of -4.14M billion.
Operating Cash Flow-4.14M
Free Cash Flow-4.14M
Free Cash Flow per Share-1.80
Dividends & Yields
Marinomed Biotech AG pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.05
52-Week Price Change9.80%
50-Day Moving Average15.31
200-Day Moving Average17.87
Relative Strength Index (RSI)39.07
Average Volume (3m)13.00
Important Dates
Marinomed Biotech AG upcoming earnings date is May 26, 2026, Before Open (Confirmed).
Last Earnings DateApr 22, 2026
Next Earnings DateMay 26, 2026
Ex-Dividend Date―
Financial Position
Marinomed Biotech AG as a current ratio of 0.74, with Debt / Equity ratio of -116.33%
Current Ratio0.74
Quick Ratio0.63
Debt to Market Cap0.49
Net Debt to EBITDA-5.30
Interest Coverage Ratio-3.71
Taxes
In the past 12 months, Marinomed Biotech AG has paid 4.00K in taxes.
Income Tax4.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Marinomed Biotech AG EV to EBITDA ratio is -17.54, with an EV/FCF ratio of -13.64.
EV to Sales6.92
EV to EBITDA-17.54
EV to Free Cash Flow-13.64
EV to Operating Cash Flow-14.03
Balance Sheet
Marinomed Biotech AG has €911.50K in cash and marketable securities with €29.09M in debt, giving a net cash position of -€28.18M billion.
Cash & Marketable Securities€911.50K
Total Debt€29.09M
Net Cash-€28.18M
Net Cash Per Share-€12.25
Tangible Book Value Per Share-€7.68
Margins
Gross margin is 25.97%, with operating margin of -55.85%, and net profit margin of -73.99%.
Gross Margin25.97%
Operating Margin-55.85%
Pretax Margin-73.95%
Net Profit Margin-73.99%
EBITDA Margin-39.45%
EBIT Margin-46.83%
Analyst Forecast
The average price target for Marinomed Biotech AG is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―